Ironwood Pharma (IRWD) Misses Q2 EPS by 12c; Reiterates Outlook

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/23/2026

1. META
2. TSLA
3. IBM
4. TXN
5. MRNA
6. SAP
7. CSX
8. LRCX
9. MRK
10. LVS

Go back to Ironwood Pharma (IRWD) Misses Q2 EPS by 12c; Reiterates Outlook

Ironwood Pharmaceuticals Reports Second Quarter 2022 Results; Maintains Full Year Guidance Due to Continued Strength of LINZESS® Prescription Demand

August 4, 2022 7:00 AM EDT

LINZESS (Iinaclotide) EUTRx prescription demand growth in Q2 2022 increased 9% year-over-year

GAAP net income of $37 million and adjusted EBITDA of $56 million; ended Q2 2022 with $504 million in cash and cash equivalents

Completes Board of Directors authorized share repurchase program; repays remaining principal amount of the 2022 Convertible Notes in cash

Reiterates 2022 guidance of U.S. LINZESS net sales growth of low single digits %, total Ironwood revenue of $420 to $430 million and adjusted EBITDA of >$250 million

BOSTON--(BUSINESS... More